Taken together, combining an SGLT-2 inhibitor with a GLP-1 receptor agonist in people with type 2 diabetes is associated with lower risk of major cardiovascular events, mortality, heart failure hospitalisations and adverse kidney outcomes compared with monotherapy based on a meta-analysis of 18 cohort studies with 1,164,774 participants [36]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.